- Home
- PCM vs ALXO Comparison
PCM vs ALXO Comparison
Compare PCM & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCM | ALXO |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 79.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCM | ALXO |
|---|---|---|
| Price | $6.17 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 29.1K | ★ 350.9K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.88 | $0.40 |
| 52 Week High | $10.20 | $2.27 |
Technical Indicators
Market Signals| Indicator | PCM | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 47.97 |
| Support Level | $6.16 | $1.29 |
| Resistance Level | $6.29 | $1.56 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 63.33 | 39.82 |
Price Performance
Historical ComparisonAbout PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.